visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Engineering a recombinant chlorotoxin as cell-targeted cytotoxic nanoparticles |
Data: | 2019 |
Resum: | The controlled oligomerization of functional proteins at the nanoscale offers the possibility to design and produce, by recombinant DNA technologies and in cell factories, improved materials and drugs in form of nanoparticles. A recombinant version of the scorpion toxin chlorotoxin (CTX), which has attracted interest due to its ability to preferentially bind cancer cells, has been engineered to self-assemble as regular 12 nm-nanoparticles that penetrate cultured cells with the same receptor-specificity than the natural toxin. These materials, that appear as promising, biocompatible and biodegradable drug carriers for cell-targeted therapy of glioma also exhibit a mild but still significant cytotoxic activity associated to the recombinant toxin, that simultaneously acts as both driver and therapeutic agent. In addition, the manipulation of the CTX-flanking regions shows a potent impact on the performance of the nanoparticles, supporting a high functional versatility of CTX-based constructs, regulatable by conventional genetic engineering and adaptable to specific therapeutic situations. |
Ajuts: | Ministerio de Ciencia e Innovación BIO2016-76063-R Instituto de Salud Carlos III PI15/00272 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-229 Agència de Gestió d'Ajuts Universitaris i de Recerca 2018/FI_B2_00051 |
Nota: | Altres ajuts: CIBER-BBN (project VENOM4CANCER) granted to AV.NS was supported by a predoctoral fellowship from the Government of Navarra, and UU is supported by PERIS program from the health department of la Generalitat de Cataluña. AV received an ICREA ACADEMIA award. |
Drets: | Tots els drets reservats. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió acceptada per publicar |
Matèria: | Recombinant proteins ; Nanoparticles ; Cancer therapies ; Targeted therapies |
Publicat a: | Science China Materials, Vol. 62, issue 6 (June 2019) , p. 892-898, ISSN 2199-4501 |
Article. Postprint 13 p, 260.3 KB |
Figura 1 1 p, 232.5 KB |
Figura 2 1 p, 109.7 KB |
Figura 3 1 p, 160.4 KB |
Informació suplementària 7 p, 100.4 KB |